Live Analyst Rating Changes 24957 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Alec Stranahan
BofA

Alec Stranahan

Bank of America Securities
Wall Street Analyst
★★★☆☆
#1386
on 13Foresight · ranked by our own returns
52%
Success Rate
+4.2%
Average Return
46 of 89 calls profitable · +1.1% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 52% of Alec Stranahan's ratings turned a profit when each position was held for 1 year — averaging +4.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

187 Buy 52 Hold 76 Sell
Alec's Stock Coverage 33 ratings · 2026-08-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CATX
Perspective Therapeutics
 Aug 14, 2026 HOLD Strong Buy
+246.2% avg upside
22 analysts
$5.00
56.15% Upside
 +0.0% ·
AKTS
Aktis Oncology, Inc.
 Aug 14, 2026 BUY Strong Buy
+29.0% avg upside
9 analysts
$34.00
36.35% Upside
 +0.0% ·
CADL
Candel Therapeutics
 Aug 14, 2026 HOLD Strong Buy
+57.0% avg upside
11 analysts
$12.00
2.33% Upside
 +0.0% ·
CRBU
Caribou Biosciences
 Aug 14, 2026 BUY Strong Buy
+602.0% avg upside
12 analysts
$5.00
216.55% Upside
 +0.0% ·
ERAS
Erasca
 Aug 14, 2026 HOLD Strong Buy
+12.3% avg upside
14 analysts
$20.00
8.77% Upside
 +0.0% ·
SANA
Sana Biotechnology
 Aug 14, 2026 BUY Strong Buy
+177.0% avg upside
14 analysts
$6.00
68.95% Upside
 +0.0% ·
MGTX
Meiragtx Holdings
 Aug 14, 2026 BUY Strong Buy
+92.9% avg upside
13 analysts
$19.00
40.63% Upside
 +0.0% ·
RXRX
Recursion Pharmaceuticals
 Aug 12, 2026 HOLD Buy
+151.6% avg upside
12 analysts
$6.00
89.84% Upside
 -4.0% ·
WVE
Wave Life Sciences
 Aug 12, 2026 BUY Strong Buy
+288.2% avg upside
28 analysts
$17.00
214.20% Upside
 +3.2% ·
RGNX
RegenXBio
 Aug 07, 2026 BUY Strong Buy
+251.0% avg upside
22 analysts
$15.00
39.34% Upside
 +0.4% ·
NVAX
Novavax
 Aug 07, 2026 SELL Hold
+186.5% avg upside
20 analysts
$7.00
13.04% Downside
 -0.1% ·
XNCR
Xencor
 Aug 07, 2026 HOLD Strong Buy
+48.3% avg upside
27 analysts
$20.00
14.35% Downside
 +12.2% ·
EDIT
Editas Medicine
 Aug 07, 2026 SELL Buy
+384.6% avg upside
33 analysts
 — +2.1% ·
NTLA
Intellia Therapeutics
 Aug 07, 2026 HOLD Buy
+224.8% avg upside
37 analysts
$17.00
42.67% Upside
 -0.2% ·
AVTX
Avalo Therapeutics
 Aug 07, 2026 BUY Strong Buy
+166.7% avg upside
20 analysts
$35.00
78.59% Upside
 +6.9% ·
ALEC
Alector
 Aug 07, 2026 SELL Buy
+407.3% avg upside
14 analysts
$1.00
49.00% Downside
 -10.1% ·
VIR
Vir Biotechnology
 Aug 07, 2026 BUY Strong Buy
+178.9% avg upside
16 analysts
$15.00
62.38% Upside
 +4.8% ·
JANX
Janux Therapeutics Inc
 Aug 07, 2026 BUY Strong Buy
+188.5% avg upside
21 analysts
$22.00
36.47% Upside
 +1.7% ·
CGON
CG Oncology, Inc.
 Aug 07, 2026 BUY Strong Buy
+14.6% avg upside
17 analysts
$88.00
17.38% Upside
 -0.1% ·
RVMD
Revolution Medicines
 Aug 06, 2026 BUY Strong Buy
-17.1% avg upside
32 analysts
$225.00
10.41% Upside
 +3.0% ·
CRSP
Crispr Therapeutics AG
 Aug 05, 2026 BUY Buy
+41.2% avg upside
41 analysts
$82.00
53.16% Upside
 +2.1% ·
TGTX
TG Therapeutics
 Aug 05, 2026 SELL Strong Buy
-8.8% avg upside
20 analysts
$21.00
56.85% Downside
 +2.3% ·
BEAM
Beam Therapeutics
 Aug 05, 2026 BUY Strong Buy
+94.4% avg upside
25 analysts
$43.00
60.67% Upside
 -1.2% ·
KRYS
Krystal Biotech
 Aug 03, 2026 BUY Strong Buy
-20.0% avg upside
20 analysts
$392.00
17.88% Upside
 +6.3% ·
MRNA
Moderna
 Jul 31, 2026 SELL Hold
+12.0% avg upside
38 analysts
$40.00
36.90% Downside
 -15.5% ·
HCM
HUTCHMED
 Jul 31, 2026 BUY Strong Buy
+151.9% avg upside
9 analysts
$16.00
31.12% Upside
 +12.8% ·
AGIO
Agios Pharma
 Jul 30, 2026 BUY Strong Buy
+84.8% avg upside
29 analysts
$46.00
37.11% Upside
 +2.5% ·
IMTX
Immatics
 May 31, 2026 BUY Strong Buy
+93.5% avg upside
15 analysts
$17.00
80.14% Upside
 -15.3% ·
BTAI
Bioxcel Therapeutics
 Mar 27, 2026 SELL Buy
+1935.5% avg upside
12 analysts
$1.00
15.88% Downside
 +10.3% ·
REGN
Regeneron
 Dec 10, 2024 SELL Strong Buy
-2.5% avg upside
58 analysts
$565.00
29.61% Downside
 +6.2% ·
LLY
Eli Lilly & Co
 Nov 01, 2024 BUY Strong Buy
-11.8% avg upside
48 analysts
$1100.00
6.84% Downside
 +6.2% ·
DMRA
Damora Therapeutics
 Aug 15, 2023 BUY Strong Buy
-7.0% avg upside
20 analysts
$5.00
83.96% Downside
 -16.5% ·
NXTC
NextCure
 Dec 02, 2022 SELL Buy
+115.4% avg upside
10 analysts
$1.00
87.86% Downside
 +14.9% ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Alec Stranahan — Frequently Asked Questions
How accurate are Alec Stranahan's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Alec's ratings were profitable over a one-year hold, with an average return of +4.2% per rating, or +1.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Alec ranked on 13Foresight?
Alec Stranahan is currently ranked #1386 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Alec cover?
Alec most recently has ratings on CATX, AKTS, CADL, CRBU, ERAS, SANA, MGTX, RXRX, WVE, RGNX, NVAX, XNCR and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.